Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07196722 · ClinicalTrials.gov registry record · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2 study of Crohn Disease, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,092
- Enrollment target
- 20
- Study locations
NCT07196722: Recruiting Phase 2 study of Crohn Disease, sponsored by Janssen Research & Development.
NCT07196722 is a Phase 2 study of Crohn Disease that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 1,092 participants, above the 190-participant average among 71 other Crohn Disease trials with a reported enrollment target (475% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07196722, a Phase 2 study of Crohn Disease, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,092 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Primary Outcome
Clinical response is defined as a greater than or equal to (\>=) 100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) score. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Icotrokinra
Study Locations (20)
California
- Clinnova Research - Anaheim
- Alliance Research Institute, LLC - Canoga Park - Canoga Park
- Southern California Research Center - Coronado
- Om Research, LLC 1 - Lancaster
- TLC Clinical Research Inc - Los Angeles
- GastroIntestinal Bioscience - Los Angeles
- Om Research, LLC 2 - Oxnard
- Clinical Applications Laboratories, Inc - San Diego
- Medical Associates Research Group, Inc. - San Diego
Florida
- American Institute of Research - Cutler Bay
- Nature Coast Clinical Research - Inverness
- Green Leaf Clinical Trials - Jacksonville
- Florida Research Center Inc. - Lakewood Rch
- Sanchez Clinical Research, Inc - Miami
- GCP Clinical Research - Tampa
Arizona
- AZ Gastro Care - Chandler
- Mayo Clinic - Scottsdale
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Connecticut
- Nuvance Health Danbury Hospital - Danbury
Georgia
- Children's Center for Digestive Health Care - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,092 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2032-10-06 |
| Phase | Phase 2 |
What NCT07196722 shows while recruiting
NCT07196722 is an interventional study that assigns participants to a tested intervention. Its 1,092 participants enrollment target places it among the larger protocols in the corpus, above the 190-participant average among 71 other Crohn Disease trials with a reported enrollment target (475% higher).
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07196722 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07196722 about?
NCT07196722 is a clinical study titled "A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease". The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
What is the current status of trial NCT07196722?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,092 participants. The study started on 2025-10-03. Estimated completion is 2032-10-06.
What conditions does trial NCT07196722 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT07196722?
The interventions under investigation include: Placebo (DRUG), Icotrokinra (DRUG).
Who is sponsoring clinical trial NCT07196722?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07196722 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07196722's enrollment target sits among peer trials
1,092 3rd of 71 higher than 69 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Standardized Microbiota Transplant Therapy in Crohn's Disease
RECRUITING · Phase 2
-
Precise Infliximab Exposure and Pharmacodynamic Control
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant for Crohn's Disease
RECRUITING · Phase 2
-
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
- NCT06585241 · 1,094 participants · Phase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
- NCT06191744 · 1,095 participants · Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI